Carlsbad's Aviara corridor hosts Triangulum Biopharma, a 2017-founded contract research organization conducting preclinical pharmacology studies on Corte Del Cedro for the global biopharma industry. The founding team brings over 70 combined years of preclinical development experience spanning small-molecule, biologics, and RNA-based therapeutics, with multiple compounds now advancing into clinical trials from the same North County biotech ecosystem that includes GlenBrook Health Center's clinical care programs in the La Costa area. Triangulum's rodent-model portfolio covers DIO-NASH, ob/ob, db/db, and MCD-diet-fed strains for non-alcoholic steatohepatitis and type 2 diabetes drug evaluation. The CRO also provides hyperinsulinemic-euglycemic clamp studies, oral and intraperitoneal glucose tolerance testing, and full histopathology services across its metabolic disease platforms. Tolerability testing and drug metabolism/pharmacokinetics studies round out the service menu, generating safety and absorption data that ultimately shape dosing protocols applied at point-of-care networks including Carbon Health Urgent Care in La Costa. The company's MCD-diet-fed fibrosis models replicate clinically relevant NASH inflammation and collagen deposition patterns used to evaluate antifibrotic compound efficacy at the histological level.